Scholarlink

Background/Objectives <p>Zinc plays a crucial role in cirrhosis. Recent American College of Gastroenterology (ACG) guidelines recommend zinc supplementation for patients with cirrhosis and hypozincemia. However, standardized screening protocols remain unavailable, and routine serum zinc evaluation may not be cost-effective or appropriate. This study aims to determine the prevalence, risk factors, and clinical impact of zinc deficiency while developing a standardized tool for its evaluation.</p> Subjects/Methods <p>This prospective study included 110 patients with cirrhosis attending outpatient clinics. Serum zinc levels were measured, and data on demographics, cirrhosis severity, complications, and nutritional status were collected. Participants were monitored over a 6-month period to evaluate clinical outcomes.</p> Results <p>Zinc deficiency was observed in 60% of patients and linked to new/worsening ascites (hazard ratio (HR) 2.8; 95%confidence interval (CI): 1.6–14.1; <i>p</i> = 0.021). Independent risk factors included female gender, non-hepatitis B/C cirrhosis, Child-Pugh B/C, and serum albumin &lt;3.5 g/dL. A novel predictive tool, the Zinc-FANC score, was developed with the following criteria: Female gender (1 point), Albumin &lt;3.5 g/dL (2 points), Non-hepatitis B/C (1 point), and Child-Pugh B/C (1 point). The score categorized patients into low-risk (score 0), medium-risk (scores 1–2), and high-risk (scores 3–5) groups. The high-risk group showed a specificity of 97.7%, while the low-risk group demonstrated a sensitivity of 95.5%.</p> Conclusion <p>Zinc deficiency was common and linked to adverse outcomes. The Zinc-FANC score demonstrates potential utility in guiding zinc screening protocols in patients with cirrhosis; however, external validation in diverse clinical settings is warranted before its implementation in routine practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk factors, clinical outcomes, and the development of a pragmatic zinc deficiency screening tool in patients with cirrhosis: a prospective cohort study

  • 期刊论文

  • 发表日期：

    2025年11月24日

查看全文
  • Narisorn Lakananurak,
  • Phatcharaporn Chanwigoon,
  • Warasinee Hathayamat

摘要

Background/Objectives

Zinc plays a crucial role in cirrhosis. Recent American College of Gastroenterology (ACG) guidelines recommend zinc supplementation for patients with cirrhosis and hypozincemia. However, standardized screening protocols remain unavailable, and routine serum zinc evaluation may not be cost-effective or appropriate. This study aims to determine the prevalence, risk factors, and clinical impact of zinc deficiency while developing a standardized tool for its evaluation.

Subjects/Methods

This prospective study included 110 patients with cirrhosis attending outpatient clinics. Serum zinc levels were measured, and data on demographics, cirrhosis severity, complications, and nutritional status were collected. Participants were monitored over a 6-month period to evaluate clinical outcomes.

Results

Zinc deficiency was observed in 60% of patients and linked to new/worsening ascites (hazard ratio (HR) 2.8; 95%confidence interval (CI): 1.6–14.1; p = 0.021). Independent risk factors included female gender, non-hepatitis B/C cirrhosis, Child-Pugh B/C, and serum albumin <3.5 g/dL. A novel predictive tool, the Zinc-FANC score, was developed with the following criteria: Female gender (1 point), Albumin <3.5 g/dL (2 points), Non-hepatitis B/C (1 point), and Child-Pugh B/C (1 point). The score categorized patients into low-risk (score 0), medium-risk (scores 1–2), and high-risk (scores 3–5) groups. The high-risk group showed a specificity of 97.7%, while the low-risk group demonstrated a sensitivity of 95.5%.

Conclusion

Zinc deficiency was common and linked to adverse outcomes. The Zinc-FANC score demonstrates potential utility in guiding zinc screening protocols in patients with cirrhosis; however, external validation in diverse clinical settings is warranted before its implementation in routine practice.